Study in eBioMedicine shows strong disease control and survival benefits across multiple tumor types with minimal toxicity
Intensity Therapeutics (INTS), a late-stage biotechnology company developing innovative cancer therapies, announced the publication of its Phase 1/2 clinical trial results for its investigational drug INT230-6 in eBioMedicine, a Lancet Discovery Science journal. The study, titled “Safety and Efficacy of Intratumourally Administered INT230-6 in Adult Patients with Advanced Solid Tumours,” highlights significant clinical outcomes in patients with metastatic or treatment-refractory cancers.
The trial evaluated 64 heavily pretreated patients across more than 20 cancer types. INT230-6 achieved a 75% disease control rate and a median overall survival (mOS) of 11.9 months, notably higher than historical benchmarks of 4–7 months for similar patients. Among a metastatic sarcoma subgroup, median survival reached 21.3 months.
Exploratory analyses revealed that patients receiving INT230-6 doses covering more than 40% of their total tumor burden showed superior outcomes — 83% disease control and 18.7-month mOS, compared to 50% and 3.1 months in lower-dose groups. Remarkably, 20% of these patients experienced shrinkage of uninjected tumors, indicating a systemic “abscopal” immune effect.
No dose-limiting toxicities were reported, and over 95% of active agents remained within injected tumors, demonstrating strong safety and pharmacokinetic control.
“This therapy showed both direct tumor destruction and immune activation,” said Dr. Jacob Thomas of USC’s Norris Comprehensive Cancer Center. Dr. Anthony El-Khoueiry added that INT230-6 “elicited T-cell infiltration and immune engagement even in immunologically cold tumors.”
CEO Lewis H. Bender emphasized that these results could represent the first local therapy to extend survival in metastatic disease. Building on this success, Intensity has launched Phase 3 trials in sarcoma and additional randomized studies in other solid tumors.
You might like this article:Core Scientific Scraps $9 Billion Sale to CoreWeave After Shareholder Rejection
